652 related articles for article (PubMed ID: 16987835)
21. Bosentan for digital ulcers in patients with systemic sclerosis.
Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
[TBL] [Abstract][Full Text] [Related]
22. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
Denton CP; Hachulla É; Riemekasten G; Schwarting A; Frenoux JM; Frey A; Le Brun FO; Herrick AL;
Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis.
Ramos-Casals M; Brito-Zerón P; Nardi N; Claver G; Risco G; Parraga FD; Fernandez S; Julià M; Font J
Rheumatology (Oxford); 2004 Nov; 43(11):1454-6. PubMed ID: 15502001
[No Abstract] [Full Text] [Related]
25. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
[TBL] [Abstract][Full Text] [Related]
27. Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis.
Dunne J; Dutz J; Shojania K; Ng B; van Eeden S
Rheumatology (Oxford); 2006 Jul; 45(7):911-2. PubMed ID: 16531439
[No Abstract] [Full Text] [Related]
28. Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval.
Agard C; Carpentier PH; Mouthon L; Clerson P; Gressin V; Bérezné A; Diot E; Jego P; Lok C; Sparsa A; Chatelus E; Van Kien AK; Quéré I; Sibilia J; Hachulla E
Scand J Rheumatol; 2014; 43(5):398-402. PubMed ID: 24720440
[TBL] [Abstract][Full Text] [Related]
29. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
30. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
31. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
[TBL] [Abstract][Full Text] [Related]
32. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
33. [Serial computed thermography for Raynaud's phenomenon of patient with progressive systemic sclerosis (PSS)].
Tomono N; Kuriyama T; Mori M; Takahashi Y; Mitsuda T; Aihara Y; Yokota S
Ryumachi; 1996 Jun; 36(3):522-7. PubMed ID: 8779789
[TBL] [Abstract][Full Text] [Related]
34. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
35. Digital ulcers: overt vascular disease in systemic sclerosis.
Steen V; Denton CP; Pope JE; Matucci-Cerinic M
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii19-24. PubMed ID: 19487218
[TBL] [Abstract][Full Text] [Related]
36. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
Correa MJ; Mariz HA; Andrade LE; Kayser C
Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
[TBL] [Abstract][Full Text] [Related]
37. Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity.
Pauling JD; Reilly E; Smith T; Frech TM
Arthritis Care Res (Hoboken); 2019 Aug; 71(8):1119-1126. PubMed ID: 30133174
[TBL] [Abstract][Full Text] [Related]
38. No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis.
Hettema ME; Zhang D; Stienstra Y; Smit AJ; Bootsma H; Kallenberg CG
Clin Rheumatol; 2009 Jul; 28(7):825-33. PubMed ID: 19350343
[TBL] [Abstract][Full Text] [Related]
39. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
[TBL] [Abstract][Full Text] [Related]
40. Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
Funauchi M; Kishimoto K; Shimazu H; Nagare Y; Hino S; Yano T; Kinoshita K
Rheumatol Int; 2009 May; 29(7):769-75. PubMed ID: 19037604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
